Baird Maintains Neutral on Beta Bionics, Raises Price Target to $16
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $14 to $16.
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and raises the price target from $14 to $16.